Background. The lymphatic system is a major route for cancer cell dissemination, and a potential target for antitumor therapy. Despite ongoing interest in this area of research, the real-time behavior of cancer cells trafficking in the lymphatic system is poorly understood due to lack of appropriate tools to image this process.
INTRODUCTION
Cancer invasion of the lymphatic system and spread to draining lymph nodes is a common occurrence and is often a first step of the metastatic pathway. Therefore, lymphatic spread is an important component of staging and prognosis [1] [2] [3] . Clearly a thorough understanding of the interaction of host lymphatic tissue with invading cancer cells is critical to our ability to fight cancer metastasis.
Current technologies have been able to transiently mark lymphatic architecture [4 -6] , but no durable strategy for in vivo lymphatic visualization has yet been developed. Ex vivo immunohistochemical staining of sectioned lymphatic tissue has revealed information on the lymphatic system and its response to specific growth factors, but these are static studies and do not reveal information on the dynamics of cancer cell trafficking within lymphatics [3] .
The discovery of lymphatic endothelium-specific markers have allowed the distinction of blood versus lymphatic vessels in histological sections, greatly improving our ability to evaluate lymphatic-specific phenomena [7] . We have combined the staining specificity of a monoclonal antibody that binds to murine LYVE-1 located on lymphatic endothelial cells, with the power of in vivo fluorescence imaging to facilitate real-time color-coded imaging of lymphatic vessels and tumor cell trafficking in a living animal.
MATERIALS AND METHODS

Antibody Conjugation
Monoclonal anti-mouse LYVE-1 antibody (rat IgG2 a ) was purchased from R&D Systems Inc. (Minneapolis, MN). The AlexaFluor 488 monoclonal antibody labeling kit was purchased from Molecular 1 To whom correspondence and reprint requests should be addressed at 3855 Health Sciences Drive #0987, La Jolla, CA 92093-0987. E-mail: mbouvet@ucsd.edu.
Probes Inc. (Eugene, OR). The AlexaFluor 488 reactive dye contains a tetrafluorophenyl ester group that reacts with the primary amines of proteins to form stable protein-dye conjugates. Monoclonal antimouse LYVE-1 was reconstituted at 1 mg/mL in phosphate-buffered saline (PBS). One hundred microliters of the 1 mg/mL solution was added to the AlexaFluor 488 reactive dye mixture. The pH of the antibody-dye mixture was adjusted to 8.0 -8.3 using 1M sodium bicarbonate as needed. The mixture was then allowed to incubate for 1 hour at room temperature, followed by overnight incubation at 4°C. The conjugated antibody was then separated from the remaining unconjugated dye on a purification column by centrifugation. Antibody and dye concentrations in the final sample were determined spectrophotometrically based on absorbance of the final purified conjugate at 280 and 494 nm, respectively.
Control purified rat IgG was purchased from R&D Systems Inc. For conjugation of this antibody, the AlexaFluor 488 protein labeling kit was purchased from Molecular Probes Inc. The control IgG was diluted to 2 mg/mL in PBS. Five hundred microliters of the diluted antibody was added to the AlexaFluor 488 reactive dye mixture. Sodium bicarbonate 1M was used to adjust the pH of the antibodydye mixture to 8.0 -8.3. The mixture was allowed to incubate for 1 hour at room temperature, followed by overnight incubation at 4°C. The conjugated antibody was then separated from the remaining unconjugated dye on an elution column by gravity. Antibody and dye concentrations in the final purified sample were determined spectrophotometrically based on absorbance of the final conjugate at 280 and 494 nm, respectively. All conjugated antibody used in this study had reached a minimum molar ratio of 1:4 mol IgG:mol dye.
Immunohistochemical Staining
Slides of murine axillary lymphatic tissue were fixed using icecold acetone for 2 minutes, then stored at Ϫ80°C. The slides were then blocked for 12 hour with 5% bovine serum albumin in PBS at 4°C. They were then washed with PBS and incubated with a 1:40 dilution of labeled antibody (0.043 g/mL concentration) for 3 hour at room temperature. The slides were then rinsed with PBS and secured with 80% glycerol and a coverslip. Slides were imaged using a Nikon DE-300 fluorescent inverted microscope (Nikon Instruments, Inc., Melville, NY) and Spot camera RD for image acquisition. Image analysis was done using Metamorph software (Universal Imaging Corporation, Sunnyvale, CA).
Murine mesentery samples from naïve nude mice were spread over glass slides and fixed using acetone at room temperature for 2 minutes and then stored at Ϫ80°C. Slides were blocked for 12 hour in 5% bovine serum albumin in PBS at 4°C, washed with PBS, and incubated with 1:100 dilution of labeled antibody (0.02 g/mL concentration) for 3 hours at room temperature. Following staining, the slides were rinsed again with PBS and secured with 80% glycerol and a coverslip and then imaged using fluorescence inverted microscopy as above.
Cell Culture
The human pancreatic cancer cell line XPA-1 was a gift from Dr. Anirban Maitra at Johns Hopkins University [8 -10] . Cells were maintained in RPMI 1640 media supplemented with 10% fetal bovine serum and 2 mM glutamine from Gibco-BRL, Life Technologies, Inc. (Grand Island, NY). All cells were cultured at 37°C in a 5% CO 2 incubator.
Red Fluorescent Protein (RFP) Retroviral Transduction and Selection
The pDsRed-2 vector from Clontech Laboratories, Inc. (Palo Alto, CA) was used for stable expression of RFP in the human pancreatic cancer cell line XPA-1. The pDsRed-2 retrovirus, which also contains a neomycin-resistance gene, was produced in PT67 packaging cells [11, 12] . Twenty percent confluent XPA-1 cells were incubated with retroviral supernatants of the packaging cells for 24 h. Fresh medium was then replenished and the cells were allowed to grow for another 12 h. This was repeated until high levels of RFP expression were observed under fluorescence microscopy. Cells were then trypsinized and harvested and subcultured in selective media containing Geneticin G418 from Invitrogen Corp. g/mL. Clones with high RFP expression were isolated and grown for 10 passages in the absence of G418 to select for stable in vitro expression of RFP.
In Vivo Lymphatic Imaging with LYVE-1
Six-week-old athymic nude mice were anesthetized using 50% ketamine, 38% xylazine, and 12% agepromazine maleate injected intramuscularly at a dose of 2 L/g. A ventral skin flap was elevated under sterile conditions exposing the inguinal and axillary lymph nodes as well as the interconnecting lymphatics of the anterior abdominal wall. Antibody (2.4 g conjugated LYVE-1 or control IgG) or fluorescein isothiocyanate (FITC)-dextran (molecular weight, 200,000; Sigma-Aldrich, St. Louis, MO) in a final volume of 50 L was injected slowly into the tissues around the exposed inguinal lymph node using a 50 L Hamilton syringe (Hamilton Co., Reno, NV). For repeated imaging, the skin flap was sutured closed between imaging sessions, again under sterile conditions, using 6-0 polysorb surgical suture (US Surgical, Norwalk, CA).
The inguinal lymph node, draining lymphatics, and axillary lymph node were imaged using the OV-100 Small Animal Imaging System (Olympus Corp., Tokyo, Japan) containing an MT-20 light source from Olympus Biosystems (Planegg, Germany) and DP70 CCD camera from Olympus Corp. Images were processed for contrast and brightness and analyzed with the use of Photoshop Element-4. Animals were imaged immediately after antibody or FITC injection and at 4, 12, 24, 36, 48, and 72 hour post-injection. A total of three mice were used for the in vivo time course evaluation. All animal studies were conducted in accordance with the principles and procedures outlined in the NIH Guide for the Care and Use of Animals under Assurance Number A3873-1.
In Vivo Tumor Cell Trafficking
Confluent XPA-1 RFP cells were harvested by trypsinization and washed with warm PBS. The cells were diluted to 10 7 cells/mL in PBS to a total volume of 200 L. The cells were slowly and directly injected into the area around the inguinal lymph node using a 1 mL 27G2 latex-free syringe (Becton Dickinson, Franklin Lakes, NJ) 4 hours after administration of AlexaFluor-labeled monoclonal antimouse LYVE-1 as described above. Cell movement through the draining lymphatics of the inguinal lymph node and the afferent lymphatics of the axillary lymph node was imaged in real-time using the OV-100 Small Animal Imaging System. Six animals were used in the in vivo imaging of tumor cell trafficking over the course of this study.
RESULTS
In vivo lymphatic imaging using AlexaFluor-conjugated LYVE-1 provided a specific and durable signal. Delivery of conjugated LYVE-1 to the mouse inguinal lymph node allowed both immediate and delayed visualization of the draining inguinal lymphatics as well as the afferent lymphatics of the receiving axillary lymph node (Fig. 1A-C) . This signal was detectable out to at least 48 hour post-injection with the clearest signal present at 4 hour after antibody delivery. Animals imaged similarly after administration of control conjugated IgG or FITC-dextran to the inguinal lymph node showed minimal signal in the draining lymphatics at 4 hour post-injection and no signal at 12 hour post-injection (Fig.  2) . Durable in vivo staining of mouse lymphatics was observed in all three animals imaged over time.
Immunostaining of murine lymphatic tissue using AlexaFluor-conjugated LYVE-1 is specific to lymphatic endothelium. Specificity of the conjugated LYVE-1 antibody was verified by ex vivo analysis of mouse lymphatic tissue. Murine axillary lymphatic tissue revealed a strong fluorescent signal in the lymphatic vessels around the lymph node periphery with sparing of the germinal centers (Fig. 3A-C) . Likewise, staining of prepared mouse mesentery showed specific staining of lymphatic vessels coursing alongside mesenteric arteries and veins with low background (Fig. 3D) . In addition, specific in vivo binding of the antibody-AlexaFluor conjugate to the endothelium of the lymphatic vessels allowed clear delineation of the vessel walls and valves ( Fig. 3E and F) .
Tumor cell trafficking through mouse lymphatics imaged with AlexaFluor-conjugated LYVE-1 was imaged in vivo in real-time using live-mouse fluorescent imaging technology previously developed in our laboratory [13] [14] [15] . After in vivo staining of mouse lymphatic endothelium with AlexaFluor-conjugated LYVE-1, human pancreatic tumor cells expressing RFP were injected into the inguinal lymph node and surrounding tissues and lymphatic trafficking was imaged. The RFP-expressing cancer cells were clearly visible within the lymphatic vessels trafficking from the inguinal lymph node to the axillary lymph node (Fig. 4) . Fig.  4A -F shows trafficking of RFP cancer cells in a fluorescent LYVE-1-labeled lymphatic. Fig. 4G shows the RFP labeled cancer cells collecting in the receiving axillary lymph node that has also been labeled with the fluorescent LYVE-1 antibody. Cell trafficking through the lymphatic vasculature and into the receiving lymph node can also be imaged and recorded on video in real-time using the Olympus OV-100 Small Animal Imaging System. In all six animals evaluated for in vivo imaging of tumor cell trafficking, the RFPexpressing cancer cells could be reliably seen in contrast against the green-labeled lymphatics.
DISCUSSION
Cancer invasion of the lymphatic system and spread to draining lymph nodes are a common occurrence and are often a first stop of the metastatic pathway [3] . Therefore, lymphatic spread is a significant component of staging and prognosis in many solid tumors [1, 2] . Recent results suggest that lymphangiogenesis itself can contribute to tumor metastasis [16, 17] . In some cases tumor cells appear to influence the host lymphatic architecture, possibly paving the way for their own metastasis [18] , although this influence varies with different tumor types [19 -21] . These findings underscore the importance of a thorough understanding of the interaction of host lymphatic tissue with invading cancer cells. rounding environment, including the host lymphatic system, would greatly contribute to our ability to understand tumor invasion and metastasis. In particular, imaging of the real-time dynamics of cancer cell trafficking to lymph nodes is critical to the fundamental understanding of metastasis.
Current technologies for lymphatic imaging are often limited to the general uptake of molecules from the interstitial space, affording only transient and nonspecific visualization of the lymphatic system. Ex vivo immunohistochemical staining of sectioned lymphatic tissue has revealed information on the lymphatic system and its response to specific growth factors [3] . However, these are static studies and do not reveal information on the dynamics of cancer cell trafficking in lymphatics. Experimental in vivo lymphangiography relies on the lymphatic uptake of molecules such as ferritin or FITC-dextran [4 -6] . In clinical practice, lymphatic mapping employs the use of radiocolloid solutions or dyes [22, 23] . While these strategies can provide information about lymphatic vessel density and function, they are transient and nonspecific and do not yield information on real-time cancer cell trafficking through lymphatic networks.
LYVE-1 is a hyaluronic acid receptor with sequence similarity to CD44 expressed on lymphatic endothelial cells [24] . This marker as well as other lymph-specific markers such as Podoplanin and vascular endothelial growth factor receptor-3 have made it possible to distinguish between lymphatic and vascular endothelium in ex vivo tissue staining, as these markers are generally not expressed on the endothelial cells lining arteries and veins [7] . Monoclonal antibodies specific for LYVE-1 have been used in immunohistochemical staining for some time, but to date have not been used for in vivo lymphangiography. We describe here a novel real-time dual-color imaging technology in live mice using fluorescein-conjugated LYVE-1 antibodies to simultaneously visualize lymphatic vessels and lymphatic trafficking of fluorescent-protein-labeled tumor cells traveling within them.
By using monoclonal antibodies specific for the lymphatic endothelium, the technology described in this report enables superior visualization of the anatomy of the lymphatic vessels themselves. Most importantly, the signal remains within the local lymphatic vessels for up to 48 h, conferring ability to image intralymphatic cancer cell trafficking in real-time. Because the antibody-AlexaFluor conjugate can outline the vessel wall rather than merely filling the lumen, we are able to follow cell movement throughout the lymphatic system using tumor cells engineered to express a different colored fluorescent protein, in this case, RFP.
A recent report showed expression of LYVE-1 on a rare subset of tissue macrophages, which may account for some of the LYVE-1-positive cells found in immunohistochemical staining of tumor tissue [25] . Because the uptake of the conjugated antibody relies on functional lymphatics, the likelihood that macrophages contribute significantly to our in vivo signal is very low. There has also been a suggestion that LYVE-1 can stain blood vessels in special cases [6] . However, as can be seen in Fig. 1B and C and Fig. 3D , no blood vessels appear to be stained in our model with LYVE-1.
In summary, we have taken advantage of combining lymphatic-specific marker LYVE-1 and fluorescent protein-labeled cancer cells to develop a model system for real-time color-coded imaging of the interaction of tumor cells with the host lymphatic system. Cancercell trafficking confirms that the LYVE-1-marked structures in this model system are functional lymphatic vessels. This new technology offers unique advantages over current technologies available for in vivo lymphangiography in that lymphatic functionality (tumor-cell trafficking) is imaged in real-time and will facilitate the advancement of our understanding of both interactions of primary tumors with the host lymphatic system as well as lymphatic dissemination of cancer cells. Future studies will also determine clinical use of this powerful imaging technology.
